SDC1 and ventricular septal defect: In two double-blinded, randomized, placebo-controlled trials, syndecan-1 plasma levels were evaluated in neonates subjected to open heart surgery (neonatal trial) and in infants undergoing correction of a ventricular septal defect (VSD trial) to determine whether high-dose steroid treatment might have a protective effect on the glycocalyx.